Drug Profile
SI 001
Alternative Names: Autologous stromal vascular fraction cells/oncolytic vaccinia virus; CAL1 vaccinia virus; CAL1 VV + autologous cell; SI-001; SVF+ACAM-200; SVF-CAL1; SVF/VVLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator StemImmune
- Developer Calidi Biotherapeutics
- Class Antineoplastics; Immunotherapies; Oncolytic viruses; Stem cell therapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (Parenteral)
- 09 Oct 2019 Calidi Biotherapeutics plans to submit an Investigational New Drug (IND) application to the US FDA for phase Ib/II trials in Melanoma and Solid tumours
- 09 Oct 2019 Calidi Biotherapeutics plans a phase Ib/IIa trial for Prostate cancer, Melanoma and other Solid tumours in USA